Connect

Partners

Legal

© 2020 Celltex Therapeutics Corporation. All rights reserved.

COVID-19 Updates from Celltex Therapeutics Learn More

Celltex News

ChinaXiv Reports Clinical Remission of a Critically Ill COVID-19 Patient Treated by Human Umbilical Cord Mesenchymal Stem Cells

Posted on by

The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies.

ChinaXiv has performed a recent study that has proven significant improvement of a critically ill COVID-19 patient that was treated with the transfer of human umbilical cord mesenchymal stem cells. Celltex is continuing to monitor and participate in this effective research.

If you currently have your MSCs banked at Celltex and are wondering what options are available to you, please contact the Client Services team today by completing the form on our Request a Consultation page, by calling (713) 590-1000 or sending an email to info@celltexbank.com. If you are not a client but would like to bank your MSCs, please complete our online client assessment and a Client Services Coordinator will contact you.

More Recent News

Celltex has submitted Emergency Expanded Access Clinical Study for Subjects with Coronavirus 2019 (COVID-19) using multiple dose Infusions of Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)

Read More

Aging & Disease Reports Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

Read More